Fondazione Istituto Italiano Di Tecnologia

University of California

Fondazione Istituto Italiano Di Technologia

Università Degli Studi Di Parma

Università Degli Studi Di Urbino "Carlo Bo"

Fondazione Per La Ricerca Sulla Fibrosi Cistica-on-Lus

Istituto Giannina Gaslini

Instituto Giannina Gaslini

Istituto Giannina Gasiini

Fondazione Per La Ricerca Sulla Fibrosi Cristica—onlus

Universita Degli Studi Di Urbino

Fondazione Per La Ricerca Sulla Fibrosi Cistica - Ets

Fabio Bertozzi

Tiziano Bandiera

Nicoletta Pedemonte

Emanuela Caci

Loretta Ferrera

Federico Sorana

Luis Juan Vicente Galietta

Paolo Di Fruscia

Daniele Piomelli

Marco Mor

Giorgio Tarzia

Angelo Mario Reggiani

Andrea Nuzzi

Stefano Ponzano

Annalisa Fiasella

Francesco Berti

Alejandra Rodriguez Gimeno

Chiara Pagliuca

Francesca Giacomina

Silvia Pontis

Frederico Sorana

Simone Giovani

Giorgia Zaetta

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Pyrazole derivatives for the treatment of cystic fibrosis

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.

Compounds and compositions for the treatment of cystic fibrosis

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities. 

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof:  It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1:  wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions

Heterocyclic derivatives for the treatment of cystic fibrosis

Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolyzing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.

Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatment

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors

Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

Growing community of inventors

Genoa, Italy

Fabio Bertozzi